BRAF Inhibitor, LGX818, Utilizing a Pulsatile Schedule in Patients With Stage IV or Unresectable Stage III Melanoma Characterized by a BRAFV600 Mutation
Clinical trial NCT01894672 · COMPLETED
Trial details
- NCT number
- NCT01894672
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2013-07-01
- Primary completion
- 2016-03-17
- Enrollment
- 7
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.